BRAINSTORM CELL THERAPEUTICS INC. 8-K

What Happened
Brainstorm Cell Therapeutics, Inc. (BCLI) announced and furnished a press release on March 31, 2026 reporting its financial results for the year ended December 31, 2025. The company filed the information on Form 8‑K under Item 2.02 and furnished the full press release as Exhibit 99.1.

Key Details

• Press release date: March 31, 2026.
• Reporting period: year ended December 31, 2025 (financial results announced).
• Filing: Form 8‑K (Item 2.02 — Results of Operations and Financial Condition); press release furnished as Exhibit 99.1.
• Cover page interactive XBRL (Inline XBRL) included with the filing (Exhibit 104).

Why It Matters
This 8‑K notifies investors that Brainstorm has publicly released its full-year 2025 financial results; those results can affect the company’s stock valuation, outlook and investor decisions. Retail investors should read the furnished press release (Exhibit 99.1) and related SEC filings for the detailed figures—revenue, net income/loss, cash position and any management commentary—before making investment decisions.